Orion – 4 trial: Inclisiran effective in reducing cholesterol - Video

Published On 2022-02-12T11:04:38+05:30 | Updated On 12 Feb 2022 11:04 AM IST

Overview

Inclisiran is a popular drug, studied for its effect to control bad cholesterol or LDL levels in blood, a proprotein convertase subtilisin/kexin type synthesis inhibitor which has been found to reduce LDL-cholesterol by about 50-60%. High cholesterol is a serious health issue that needs to be managed immediately, several medications to prevent cholesterol levels in blood are presently available in market.

ORION-4 in ClinicalTrials.gov investigated the effects of inclisiran on major adverse cardiovascular events. Approximately 15,000 participants aged 55 years or older with pre-existing atherosclerotic cardiovascular disease were randomized between inclisiran sodium 300 mg and matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) in a 1:1 ratio for a planned median duration of about 5 years. So far inclisiran is effective in preventing heart attacks and strokes.

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751